Dr. Reddy's Laboratories Limited has informed the Exchange regarding Change in Auditors of the company.
DRREDDY · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.8 pts less than Nifty 100 and 0.3 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
The Board of Directors of Dr. Reddy's Laboratories, at its meeting held on May 9, 2025, approved audited financial results for Q4 and full year ended March 31, 2025. FY25 consolidated revenue grew 17% YoY to Rs. 325,535 Mn and profit attributable to equity holders rose 2% YoY to Rs. 56,544 Mn, with Q4 revenue up 20% YoY at Rs. 85,060 Mn. The Board recommended a final dividend of Rs. 8 per equity share (face value Rs. 1) for FY25, with record date fixed as July 10, 2025 and 41st AGM scheduled for July 24, 2025. Mr. G V Prasad (promoter) was re-appointed as Co-Chairman & Managing Director for another 5 years effective January 30, 2026, subject to shareholder approval. M/s Makarand M Joshi & Co. was appointed as Secretarial Auditors for a 5-year term from April 1, 2025. The Statutory Auditors issued an 'Unmodified Opinion' on the financial statements, referencing a prior letter dated March 21, 2025 regarding the auditor change.
Strong FY25 results driven by the recently acquired Haleon NRT business and steady growth in Global Generics and PSAI segments should support investor sentiment. The Rs. 8 per share dividend provides cash returns to shareholders, while G V Prasad's re-appointment ensures continued leadership stability.